Another group of therapeutic agents (Table 6) [24,25,26,27,28,29,30] currently having a significant role in targeted therapy for older AML patients is FLT3 (45–47) inhibitors, particularly concerning the R/R setting [144,145,146,147]. This evidence concerns the gene FLT3 and acute myeloid leukemia.